Bosutinib: Promising New TKI Treament Option for CML

patientpower has 2232 videos Subscribe Here

Description: In this video interview from ASH 2011, Dr. Carlo Gambacorti-Passerini, a prominent CML researcher from the University of Milan Bicocca, gives us an update on bosutinib, a newer Tyrosine Kinase Inhibitor (TKI) that he has studied in-depth. Once approved, bosutinib may provide one more option for patients and their physicians to better treat the disease while managing side effects.
Shared By : patientpower
Posted on : 03/20/12
Added : 5 years ago
Category : General